![Ken Pastor](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ken Pastor
Founder at CTI Life Sciences Fund
Ken Pastor active positions
Companies | Position | Start | End |
---|---|---|---|
GLyPharma Therapeutic, Inc.
![]() GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Director/Board Member | - | - |
CTI Capital, Inc.
![]() CTI Capital, Inc. Investment ManagersFinance CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal. | Private Equity Investor | - | - |
CTI Life Sciences Fund
![]() CTI Life Sciences Fund Miscellaneous Commercial ServicesCommercial Services CTI Life Sciences Fund provides life science related services. The private company is based in Montréal, Canada. The Canadian company was founded in 2006 by Kenneth Pastor. | Founder | - | - |
Corporate Officer/Principal | - | - |
Career history of Ken Pastor
Former positions of Ken Pastor
Companies | Position | Start | End |
---|---|---|---|
CTI Capital Securities, Inc.
![]() CTI Capital Securities, Inc. Investment Banks/BrokersFinance CTI Capital Securities, Inc. (CTI) is the brokerage subsidiary of CTI Capital Groupe, Inc. The firm is headquartered in Montréal and was founded in 1987. CTI provides brokerage services in the fixed-income, money market and stock markets. Their fixed-income research seeks to identify the optimal strategy for the term, duration and tactical opportunities between different sectors of the market. Their equity research focuses on continuous global monitoring of the Canadian stock market. | Analyst-Fixed Income | 21/08/2013 | - |
Institutional Sales | 21/08/2013 | - | |
CTI Fonds Mutuels
![]() CTI Fonds Mutuels Investment ManagersFinance Founded in 1987, CTI Fond Mutuels is a mutual fund manager headquartered in Montreal, Quebec. The firm is a subsidiary of CTI Capital, Inc. They manage some of the CTI mutual funds. | Analyst-Fixed Income | - | 07/12/2010 |
Portfolio Manager-Fixed Income | 07/12/2010 | - | |
Corporate Officer/Principal | 07/12/2010 | 07/12/2010 |
Training of Ken Pastor
University of Montréal | Undergraduate Degree |
Statistics
International
Canada | 7 |
Operational
Analyst-Fixed Income | 2 |
Corporate Officer/Principal | 2 |
Portfolio Manager-Fixed Income | 1 |
Sectoral
Finance | 4 |
Consumer Services | 2 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 5 |
---|---|
CTI Fonds Mutuels
![]() CTI Fonds Mutuels Investment ManagersFinance Founded in 1987, CTI Fond Mutuels is a mutual fund manager headquartered in Montreal, Quebec. The firm is a subsidiary of CTI Capital, Inc. They manage some of the CTI mutual funds. | Finance |
CTI Capital Securities, Inc.
![]() CTI Capital Securities, Inc. Investment Banks/BrokersFinance CTI Capital Securities, Inc. (CTI) is the brokerage subsidiary of CTI Capital Groupe, Inc. The firm is headquartered in Montréal and was founded in 1987. CTI provides brokerage services in the fixed-income, money market and stock markets. Their fixed-income research seeks to identify the optimal strategy for the term, duration and tactical opportunities between different sectors of the market. Their equity research focuses on continuous global monitoring of the Canadian stock market. | Finance |
GLyPharma Therapeutic, Inc.
![]() GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Health Technology |
CTI Capital, Inc.
![]() CTI Capital, Inc. Investment ManagersFinance CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal. | Finance |
CTI Life Sciences Fund
![]() CTI Life Sciences Fund Miscellaneous Commercial ServicesCommercial Services CTI Life Sciences Fund provides life science related services. The private company is based in Montréal, Canada. The Canadian company was founded in 2006 by Kenneth Pastor. | Commercial Services |
- Stock Market
- Insiders
- Ken Pastor
- Experience